Literature DB >> 9554296

Livedo vasculopathy vs small vessel cutaneous vasculitis: cytokine and platelet P-selectin studies.

M Papi1, B Didona, O De Pità, A Frezzolini, S Di Giulio, W De Matteis, D Del Principe, R Cavalieri.   

Abstract

OBJECTIVE: To assess the role of platelets and lymphocyte-related immunological mechanisms in livedo vasculopathy (LV) and cutaneous small vessel vasculitis (CSVV). Livedo vasculopathy is thought to be related to the thrombotic occlusion of small and medium-sized dermal vessels. Cutaneous small vessel vasculitis comprises a heterogeneous group of disorders in which the main pathogenetic events could be modulated by circulating cytokines.
DESIGN: Case series study of 2 groups of patients affected respectively with LV and CSVV.
SETTING: A large clinical and research institute for the study and treatment of cutaneous diseases. PATIENTS: Consecutive patients with clinically and histologically proved idiopathic LV (n = 8) and CSVV (n = 20) were studied and compared with healthy donors (n = 20). Patients with potentially correlated systemic diseases were excluded. MAIN OUTCOME MEASURES: Surface expression of platelet P-selectin and circulating level of interleukin (IL) 1beta, tumor necrosis factor alpha (TNF-alpha), IL-8, IL-2, and soluble IL-2 receptor.
RESULTS: The IL-2 and soluble IL-2 receptor levels were significantly higher in serum samples from patients with both LV (1.24 +/- 0.46 IU/mL [mean +/- SD] vs 0.46 +/- 0.24 IU/mL, P<.001; 899 +/- 368 IU/mL vs 628 +/- 132 IU/mL, P<.02) and CSVV (0.91 +/- 0.57 IU/mL, P<.02; 1087 +/- 451 IU/mL, P<.001) than in those from the healthy controls. The serum levels of IL-1beta, TNF-alpha, and IL-8 were higher in patients with CSVV than in controls (7.53 +/- 6.7 pg/mL vs 4.58 +/- 2.72 pg/mL; 23.7 +/- 12.6 pg/mL vs 10.82 +/- 2.46 pg/mL, P<.001; 37.8 +/- 46 pg/mL vs 8.25 +/- 3.53 pg/mL, P<.02, respectively). No significant difference in the serum levels of IL-1beta (7.2 +/- 4.9 pg/mL), TNF-alpha (12.9 +/- 3.47 pg/mL), and IL-8 (5.9 +/- 4.13 pg/mL) was observed in patients with LV compared with controls. An increased expression of platelet P-selectin was also detected in patients with LV in comparison with controls and patients with CSVV. The mean +/- SD percentage of positive cells for P-selectin was 43% +/- 5% in the patients with LV, 5.1% +/- 2% in the controls (P<.001), and 5.3% +/- 2% in the patients with CSVV (P<.001).
CONCLUSIONS: Taken together, these data demonstrate that different pathogenetic mechanisms are operative in LV and CSVV. In fact, platelet and lymphocyte activation is present in LV, whereas the levels of inflammatory mediators are in a normal range. In CSVV, the high serum levels of proinflammatory cytokines suggest that they are actively involved in the pathogenesis of cutaneous vasculitis.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9554296     DOI: 10.1001/archderm.134.4.447

Source DB:  PubMed          Journal:  Arch Dermatol        ISSN: 0003-987X


  12 in total

1.  Atypical presentation of pioderma gangrenosum complicating ulcerative colitis: rapid disappearance with methylprednisolone.

Authors:  Paolo Aseni; Stefano Di Sandro; Plamen Mihaylov; Luca Lamperti; Luciano-Gregorio De Carlis
Journal:  World J Gastroenterol       Date:  2008-09-21       Impact factor: 5.742

2.  Enhanced functional stability of plasminogen activator inhibitor-1 in patients with livedoid vasculopathy.

Authors:  Mehmet Agirbasli; Mesut Eren; Fatih Eren; Sheila B Murphy; Zehra A Serdar; Dilek Seckin; Tuba Zara; M Cem Mat; Cuyan Demirkesen; Douglas E Vaughan
Journal:  J Thromb Thrombolysis       Date:  2011-07       Impact factor: 2.300

Review 3.  [Livedoid vasculopathy. Pathogenesis, diagnosis and treatment of cutaneous infarction].

Authors:  T Goerge
Journal:  Hautarzt       Date:  2011-08       Impact factor: 0.751

4.  Livedoid vasculopathy associated with combined prothrombin G20210A and factor V (Leiden) heterozygosity and MTHFR C677T homozygosity.

Authors:  Noha A Irani-Hakime; Farid Stephan; Raghid Kreidy; Isabelle Jureidini; Wassim Y Almawi
Journal:  J Thromb Thrombolysis       Date:  2008-03-23       Impact factor: 2.300

5.  Plasminogen activator inhibitor-1: a potential etiological role in livedoid vasculopathy.

Authors:  Yimeng Gao; Hongzhong Jin
Journal:  Int Wound J       Date:  2020-10-11       Impact factor: 3.315

6.  Infliximab for idiopathic deep cutaneous vasculitis refractory to cyclophosphamide.

Authors:  Marcelo Derbli Schafranski; Giuliano Doretto Campanari
Journal:  Int J Vasc Med       Date:  2010-06-27

7.  A Phase II Multicenter Trial With Rivaroxaban in the Treatment of Livedoid Vasculopathy Assessing Pain on a Visual Analog Scale.

Authors:  Attyla Drabik; Carina Hillgruber; Tobias Goerge
Journal:  JMIR Res Protoc       Date:  2014-12-10

8.  Aspirin in dermatology: Revisited.

Authors:  Aditya Kumar Bubna
Journal:  Indian Dermatol Online J       Date:  2015 Nov-Dec

9.  Dermoscopic features of livedoid vasculopathy.

Authors:  Stephen Chu-Sung Hu; Gwo-Shing Chen; Chi-Ling Lin; Yang-Chun Cheng; Yung-Song Lin
Journal:  Medicine (Baltimore)       Date:  2017-03       Impact factor: 1.889

Review 10.  Lessons from dermatology about inflammatory responses in Covid-19.

Authors:  Paulo Ricardo Criado; Carla Pagliari; Francisca Regina Oliveira Carneiro; Juarez Antonio Simões Quaresma
Journal:  Rev Med Virol       Date:  2020-07-12       Impact factor: 11.043

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.